Mylan N.V. (MYL) stock had a bullish inflow of $13.74 million worth of trades on uptick and an outflow of $12.18 million in downticks on Friday. The total uptick to downtick ratio stood at 1.13. The net money flow into the stock was $1.56 million. The money flow data, which is calculated as the dollar value of composite uptick minus the downtick trades indicated bullish. The block trades had a total money flow of $1.86 million. $1.86 million of block trade during Uptick was observed, which shows continued buying by the smart money on every weakness. However, Mylan N.V. (MYL) stock traded down $0.21 , and reached $46.66, a drop of -0.44% over the previous day. On a weekly basis, the stock is 2.65%, over the previous weeks close.
Mylan N.V. (MYL) : The most positive equity analysts on Mylan N.V. (MYL) expects the shares to touch $71, whereas, the least positive believes that the stock will trade at $51 in the short term. The company is covered by 7 Wall Street Brokerage Firms. The average price target for shares are $59.14 with an expected fluctuation of $7.47 from the mean.
Mylan N.V. (NASDAQ:MYL): On Fridays trading session , Opening price of the stock was $47.04 with an intraday high of $47.06. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $46.093. However, the stock managed to close at $46.59, a loss of 0.58% for the day. On the previous day, the stock had closed at $46.86. The total traded volume of the day was 2,236,395 shares.
In a related news, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director of Mylan N.V., Maroon Joseph C Md, had purchased 1,670 shares in a transaction dated on June 3, 2016. The transaction was executed at $44.95 per share with total amount equaling $75,067.
Mylan N.V., formerly Mylan Inc., is a global pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. Mylan operates in two segments: Generics and Specialty. The Companys generic pharmaceutical business is conducted primarily in the United States and Canada (collectively, North America); Europe, the Middle East, and Africa (collectively, EMEA); and India, Australia, Japan and New Zealand (collectively, Asia Pacific). Its specialty pharmaceutical business is conducted by Mylan Specialty L.P. (Mylan Specialty). The Companys API business is conducted through Mylan Laboratories Limited (Mylan India), which is included within the Asia Pacific region in its Generics Segment. Mylan provides products to customers in approximately 140 countries and territories.